Stocks · News reference

Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens

Aug 25, 2026, 4:51 PMVandana Singh

FDA approves Jazz Pharmaceuticals' Ziihera combinations for first-line treatment of HER2-positive gastroesophageal adenocarcinoma.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

SEC EDGARAug 31, 2026, 9:21 PMSEC EDGAR
8-K filing — Jazz Pharmaceuticals plc (JAZZ)
Filed: 2026-08-31 AccNo: 0001193125-26-377073 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
JAZZ
BenzingaAug 31, 2026, 5:27 PMBenzinga Newsdesk
Jazz Pharmaceuticals shares are trading higher after the company announced second interim top-line overall survival results from the Phase 3 HERIZON-GEA-01 trial.
JAZZ
BenzingaAug 31, 2026, 10:04 AMBenzinga Newsdesk
Jazz Reports Ziihera Outperformed Standard Treatment In Late-Stage Cancer Trial
JAZZ
BenzingaAug 27, 2026, 6:23 AMBenzinga Newsdesk
Jazz Pharmaceuticals Prices Upsized $1.1B Offering Of 1.875% Exchangeable Senior Notes Due 2032, Announces $225.0M Concurrent Share Repurchase At $249.29 Per Share
JAZZ
BenzingaSep 1, 2026, 8:57 AMNamrata Sen
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
Trump secures drug pricing deals with nine pharma companies as Kennedy reveals intense pressure from the President to deliver.
ALC BBIO LLY NVO ONC
BenzingaAug 31, 2026, 7:44 PMBenzinga Newsdesk
Trump Administration Reaches New Drug Pricing Agreement With Nine Pharma Firms
BBIO ONC SPY TEVA